IDEAYA Biosciences, Inc. cash flow to debt ratio of -254.70% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

IDEAYA Biosciences, Inc.'s free cash flow has increased -70.78% from $-251.44M last year to $-73.47M, signaling increasing performance

IDEAYA Biosciences, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

IDEAYA Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.03 today, signaling weakened financials

IDEAYA Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

IDEAYA Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

IDEAYA Biosciences, Inc.'s profit margin has increased (-98.41%) in the last year from -3.92K% to -62.17%, signaling increasing performance

IDEAYA Biosciences, Inc.'s short-term assets of $666.73M exceed its short-term liabilities of $58.81M

IDEAYA Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

IDEAYA Biosciences, Inc.'s return on equity of -13.96%, is lower than 15.00%, indicating bad performance

IDEAYA Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

IDEAYA Biosciences, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

IDEAYA Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

IDEAYA Biosciences, Inc. has negative free cash flow, indicating cash burn

IDEAYA Biosciences, Inc.'s yearly earnings has increased -58.58% since last year from $-274.48M to $-113.70M, signaling increasing performance

IDEAYA Biosciences, Inc.'s yearly revenue has increased 3.02K% since last year from $7.00M to $218.71M, signaling increasing performance

ROIC -19.00% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

IDEAYA Biosciences, Inc.'s 3-year revenue CAGR of 62.54% is positive, indicating growing revenue over the past 3 years

IDEAYA Biosciences, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

IDEAYA Biosciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

IDEAYA Biosciences, Inc. has insufficient data to evaluate this check.

IDEAYA Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

IDEAYA Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

IDEAYA Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

IDEAYA Biosciences, Inc. has insufficient data to evaluate this check.

IDEAYA Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

IDEAYA Biosciences, Inc. has a price-to-book ratio of 3.48x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

IDEAYA Biosciences, Inc. has a price-to-sales ratio of 15.51x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue